Progress of PHF6 in acute T-lymphoblastic leukemia

VernacularTitle:PHF6在急性T淋巴细胞白血病中的研究进展
Author: Shujin WANG ¹ ; Guihua ZHU ; Yao HE ; Xingxing CHAI ; Fanjing MENG ; Yanqiu XU ; Jie WANG ; Wanchuan ZHUANG
Author Information

1. 连云港市第二人民医院血液科，连云港　222000
Keywords: Acute T-lymphoblastic leukemia; PHF6 protein, human; Mutation; Molecular targeted therapy
From: Journal of Leukemia & Lymphoma 2025;34(8):505-508
CountryChina
Language:Chinese
Abstract: Acute T-lymphoblastic leukemia (T-ALL) is a hematopoietic malignancy, and in recent years, with the advancement of combined chemotherapy and hematopoietic stem cell transplantation, the prognosis of T-ALL has improved significantly, but for patients with primary drug resistance or relapsed/refractory disease the prognosis is still poor. The plant homeodomain finger 6 (PHF6) is a tumor suppressor protein, it plays a pivotal role in T cell differentiation, epigenetic regulation and oncogenic pathway synergy, and its mutations and deletions are commonly associated with the development of T-lymphocytic leukemia. However, the underlying mechanism of PHF6 in the pathogenesis of T-ALL remains unclear. This article reviews the structure, function and mechanism of action of PHF6 in T-ALL, the important coexisting genes associated with the progression of T-ALL, and the research progress in targeted therapy.